
FORM			ATTORNEY DOCKET NO.: PTI-002							
SUPPL: STATE			TION DISCLO	SURE	APPLICA	ANT: K	Cornblith			
SIALE	MEG	FEB 0 9 2004	<u> </u>	*	SERIAL	NO.: 09/	039,957	165	5/	
					FILING DATE: March 16, 1998					
		PADENTE	U.S. 1	PATENT I	DOCUME	NTS				
EXAM.	T	DOCUMENT	DATE	NAME			CLASS	SUB	FIL	ING DATE IF
INIT.	<u> </u>	NUMBER						CLASS	APP	PROPRIATE
<u> </u>										
	<u> </u>									
	<u> </u>									
	<u> </u>									
	 									
	<u> </u>									
	<u> </u>									
						·				
			FOREIG	N PATEN	T DOCUM	MENTS				
EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	FILING DATE	ABSTRA ONLY	CT	ENGLISH LANG (Y/N)
			OTHER ART	Γ, JOURN.	AL ARTIC	CLES, ET	rc.			
EXAM. INIT.	ОТНЕ	ER DOCUMENT	S: (Including Aut	hor, Title, D)ate, Relevai	nt Pages, I	Place of Pu	blication)		
170	C23	Bosanquet, Andrew G., "Short-term In Vitro Drug Sensitivity Tests for Cancer Chemotherapy. A Summary of Correlations of Test result With Both Patient Response and Survival", Forum, vol. 4, no. 2, pp. 179-195 (1994).								
Rica	C24		Furuehauf, J.P. "In Vitro Assay-Assisted Treatment selection for Women with Breast or Ovarian Cancer", Endocrine-Related Cancer, vol. 9, pp. 171-182 (2002).							ancer",
726	C25		McGuire, William L. et al., "In Vitro Assays to Predict Drug Sensitivity and Drug Resistance", Breast Cancer Research and Treatment, vol. 12, pp. 7-21 (1988).							
75	C26	Robert, Jacques, "Chemosensitivity Testing- Prediction of Response to Anticancer Drugs Using In Vitro Assays", Electronic Journal of Oncology, vol. 2, pp. 198-210 (1999).							Vitro	
EXAMIN	VER /	126:48	one		DATE CO	NSIDER		9/04	,	



Express Mail Mailing Label No. EV 375067812 US

SHEET I OF 2

FORM PTO - 1449

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

WO2004/015065A2

ROITOMOR

B5

170

EXAMINER

02/19/04

PCT

ATTORNEY DOCKET NO.: PTI-002

07/30/03

DATE CONSIDERED 11/9/04

Y

APPLICANT(S): Kornblith

SERIAL NO.: 09/039,957

FILING DATE: March 16, 1998 GROUP: 1651 **U.S. PATENT DOCUMENTS** EXAM. DOCUMENT NUMBER DATE NAME **CLASS SUB** FILING DATE IF INIT. **CLASS** APPROPRIATE 12/17/85 02/04/83 4,559,299 Rotman 160 A17 4,668,618 05/26/87 Thornthwaite 01/30/84 A18 4,816,395 03/28/89 Hancock et al. 12/19/85 A19 5,403,574 04/04/95 Piwnica-Worms 06/26/92 A20 5,705,270 01/06/98 Soon-Shiong et al. 06/07/95 A21 6,111,092 08/29/00 Williamson 06/03/98 A22 12/16/03 6,664,062 B1 Stanton 09/24/01 A23 2002/0168679 A1 11/14/02 Naus et al. 06/11/98 A24 2002/0192638 A1 12/19/02 Kornblith 07/26/02 A25 2004/0023375 A1 Kornblith et al. 02/05/04 07/30/02 A26 2004/0072722 A1 04/15/04 Kornblith et al. 01/02/03 A27 05/06/04 10/18/01 A28 2004/0086888 A1 Kornblith et al. FOREIGN PATENT DOCUMENTS EXAM. DOCUMENT DATE COUNTRY **CLASS** SUB **FILING ABSTRACT ENGLISH** INIT. CODE NUMBER CLASS DATE ONLY LANG (Y/N) PCT WO96/10742 04/11/96 Y 09/29/95 N BI Ra WO98/02038 01/22/98 PCT ¥ .; 07/10/97 B2 Ν 17. G WO02/33117A2 04/25/02 PCT B3 10/18/01 N 170 WO2004/035833A1 04/29/04 PCT 110 **B**4 10/10/03

SHEET 2 OF 2



FORM PTO - 1449

-aus-

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: PTI-002

APPLICANT(S): Kornblith

SERIAL NO.: 09/039,957

FILING DATE: March 16, 1998 GROUP: 1651

		OTHER ART, JOURN	NAL ARTICLES, ETC.					
EXAM. INIT.	ОТН	THER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)						
116	C23		sensitivity tests for cancer chemotherapy. A summary of esponse and survival," Forum 4(2):179-195 (1994).					
20	C24	Fruehauf, J.P., "In vitro assay-assisted treatment selection for women with breast or ovarian cancer," Endocrine-Related Cancer 9:171-182 (2002).						
176	C25	McGuire et al., "In vitro assays to predict drug sensitivity and drug resistance: A panel discussion," Breast Cancer Research and Treatment 12:7-21 (1988).						
26	C26	Robert, J., "Chemosensitivity testing: Prediction of response to anticancer drugs using in vitro assays," Electronic Journal of Oncology 2:198-205 (1999).						
170	C27	Kornblith, P., "Role of Tissue Culture in Prediction of Malignancy," <i>Clinical Neurosurgery</i> , Vol. 25, pp. 346-376 (1978).						
Ro	C28	Freshney, R.I., Culture of Animal Cells: A Manual of Basic Technique, 2nd edition, pp. 107, 124-126, 179, 233-234, 290 (1987).						
26	C29	Guo et al., "Direct fluorescence analysis of genetic polymorphisms by hybridization with oligonucleotide arrays on glass supports," Nucleic Acids Research 22(24):5456-5465 (1994).						
776	C30	Pfost et al., "A SNPshot: pharmacogenetics and the future of drug therapy," TIBTECH 18:334-338 (August, 2000).						
No	C31	Raju, G.C., "The histological and immunohistochemical evidence of squamous metaplasia from the myoepithelial cells in the breast," <i>Histopathology</i> 17(3):272-275 (1990).						
176-	C32	Stephens, J.C., "Single-nucleotide Polymorphisms, Haplotypes, and Their Relevance to Pharmacogenetics," Molecular Diagnosis 4(4):309-317 (1999).						
Res	C33	Tannock et al., The Basic Science of Oncology, 2nd edition, pp. 247-248, 261-265, 303-306(1992).						
110	C34	Becton-Dickinson Catalog, Anti-Cytokeratin (CAM 5.2) Reagent, pp. 1-11 (1997).						
Rem	C35	Boehringer Mannheim Catalog, Anti-Cytokeratin AE1/AE3, (1996).						
1765	C36	DAKO Catalog, Specification Sheet for Monoclonal Mouse Anti-Human Epithelial Membrane Antigen, pp. 1-2 (1996).						
EXAMINI	ER	RGITOMER	DATE CONSIDERED 11/9/04					